Cargando…
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
Mantle cell lymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Here, we present a nationwide assessment of treatment strategies, time to progression and s...
Autores principales: | Jerkeman, Mats, Ekberg, Sara, Glimelius, Ingrid, Albertsson-Lindblad, Alexandra, Entrop, Joshua P., Ellin, Fredrik, Sonnevi, Kristina, Lewerin, Catharina, Brandefors, Lena, Smedby, Karin E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389756/ https://www.ncbi.nlm.nih.gov/pubmed/37529083 http://dx.doi.org/10.1097/HS9.0000000000000928 |
Ejemplares similares
-
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
por: Ekberg, Sara, et al.
Publicado: (2022) -
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021) -
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
por: Ekberg, Sara, et al.
Publicado: (2022) -
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients
por: Harrysson, Sara, et al.
Publicado: (2022) -
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2019)